Lixte Biotech Appoints New CMO, Adds Director
Ticker: LIXT · Form: 8-K · Filed: Jul 11, 2024 · CIK: 1335105
Sentiment: neutral
Topics: management-change, board-appointment, executive-compensation
Related Tickers: LIXT
TL;DR
Lixte Biotech beefs up leadership with new CMO (McCarthy) and board member (Rabinowitz).
AI Summary
Lixte Biotechnology Holdings, Inc. announced on July 9, 2024, the appointment of Dr. John B. McCarthy as Chief Medical Officer and the election of Dr. Alan L. Rabinowitz to its Board of Directors. Dr. McCarthy's compensation includes an annual salary of $350,000, a stock option grant of 100,000 shares, and a potential bonus. Dr. Rabinowitz will receive standard director compensation.
Why It Matters
The appointment of a new Chief Medical Officer and a new board member signals potential strategic shifts and leadership changes within Lixte Biotechnology Holdings, Inc.
Risk Assessment
Risk Level: medium — Changes in key leadership roles and board composition can indicate strategic shifts or internal challenges, warranting closer observation.
Key Numbers
- $350,000 — CMO Salary (Annual compensation for Dr. John B. McCarthy.)
- 100,000 shares — Stock Options (Granted to Dr. John B. McCarthy.)
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Registrant
- Dr. John B. McCarthy (person) — Appointed Chief Medical Officer
- Dr. Alan L. Rabinowitz (person) — Elected to Board of Directors
- $350,000 (dollar_amount) — Dr. McCarthy's annual salary
- 100,000 shares (dollar_amount) — Dr. McCarthy's stock option grant
- July 9, 2024 (date) — Date of earliest event reported
FAQ
What are the specific responsibilities of the new Chief Medical Officer, Dr. John B. McCarthy?
The filing states Dr. McCarthy's appointment as Chief Medical Officer, with compensation details provided, but does not elaborate on specific day-to-day responsibilities beyond the general scope of the role.
What is the expected tenure or term for Dr. Alan L. Rabinowitz on the Board of Directors?
The filing announces the election of Dr. Alan L. Rabinowitz to the Board of Directors but does not specify the length of his term.
Are there any performance-based bonuses or incentives for Dr. John B. McCarthy beyond the stated stock options?
The filing mentions a potential bonus for Dr. McCarthy, but the specific criteria or amount are not detailed in this report.
What is the rationale behind the appointment of Dr. Alan L. Rabinowitz to the Board?
The filing announces Dr. Rabinowitz's election but does not provide the specific reasons or strategic considerations for his appointment.
What is the total compensation package for Dr. John B. McCarthy, including base salary, stock options, and potential bonus?
Dr. McCarthy's compensation includes an annual salary of $350,000, a stock option grant for 100,000 shares, and a potential bonus, the details of which are not fully specified.
Filing Stats: 636 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2024-07-11 13:55:35
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LIXT The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-24-026924.txt ( ) — 248KB
- lixt-20240709.xsd (EX-101.SCH) — 4KB
- lixt-20240709_def.xml (EX-101.DEF) — 26KB
- lixt-20240709_lab.xml (EX-101.LAB) — 36KB
- lixt-20240709_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 11, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan Chief Executive Officer